

Supporting Information

An efficient one-pot conversion of carboxylic acids into benzimidazoles via an HBTU-promoted methodology

Leonard Barasa^a and Sabesan Yoganathan^{a*}

^a *Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, Queens, New York, 11439, United States.
Fax: + 718 990 1872; Tel: +1 718 990 5215; E-mail: yoganats@stjohns.edu*

Table of Contents

1.1 General Procedure	S2
2.1 General procedure for the synthesis of benzimidazole analogs	S3
3.1 Characterizatio data for benzimidazole analogs	S3
4.1 NMR SPECTRA	S14


GENERAL PROCEDURE

All commercially available reagents were purchased and used without further purification, unless otherwise stated. Commercially available solvents (> 99.0% purity) were used for column chromatography without any further purification. Proton and carbon NMR spectra were recorded on a 400 MHz spectrometer. Proton chemical shifts are reported in ppm (δ) relative to residual DMSO- d_6 (2.49 ppm). Data are reported as follows: chemical shift (multiplicity [singlet (s), doublet (d), doublet of doublets (dd), doublet of doublets of doublets (ddd), triplet (t), quartet (q), quintet (p), sextet (h), multiplet (m)], coupling constants [Hz], integration). Carbon chemical shifts are reported in ppm with the respective solvent resonance as the internal standard (DMSO- d_6 , 39.52 ppm). Unless otherwise noted, all NMR spectra were acquired at ambient temperature. Infrared spectra (thin film) were recorded on a FT-IR, ν_{\max} (cm^{-1}) and are partially reported. Analytical thin-layer chromatography (TLC) was performed using Silica Gel 60 Å F254 precoated plates (0.25 mm thickness). The following visualization methods were used for monitoring reactions and column chromatography: UV absorption by fluorescence quenching; Ninhydrin spray (Ninhydrin: acetic acid: *n*-butanol/ 0.6g: 6mL: 200mL) or PMA stain (phosphomolybdic acid, H_2SO_4). Flash column chromatography was performed using Flash Silica Gel (32-63 micron). Mass spectrometry data were collected on a UPLC/MS instrument equipped with a reverse-phase C18 column (1.7 μm particle size, 2.1 x 50 mm), dual atmospheric pressure chemical ionization (API)/electrospray (ESI) mass spectrometry detector, and photodiode array detector.

GENERAL PROCEDURE FOR THE SYNTHESIS OF BENZIMIDAZOLE ANALOGS


To a solution of commercially available carboxylic acid (1.0 equiv) in 30 mL of toluene or DMF was added N-ethyldiisopropylamine (1.9 equiv) and the solution was stirred for 10 min at room temperature. To the stirring solution, HBTU (2 equiv) was added and the reaction mixture stirred for another 10 min. To the stirring reaction mixture, O-phenylenediamine (1 equiv) was added and stirred for 3-4 hours. Thereafter, the reaction was heated under reflux for 3 hours. The reaction was cooled to room temperature, after which the solvent was removed *in vacuo* in the case of toluene, but for DMF, the reaction mixture was diluted with water and products were extracted using ethyl acetate (EtOAc). The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated *in vacuo*. The crude product was purified using column chromatography using hexanes/EtOAc in an increasing polarity up to 1:1 mixture. The fractions containing the desired product were concentrated and recrystallized in hexanes/EtOAc (1:1) to yield the product as a white solid. All the compounds were characterized by 1D (^1H and ^{13}C) NMR, FT-IR, and LC/MS.

***tert*-butyl (1*H*-benzo[*d*]imidazol-2-yl)methylcarbamate (15a)**




White solid, 0.47 g, 91%; R_f 0.22 (9:1/ CH_2Cl_2 :MeOH); IR: 3343.8, 2923.9, 1939.1, 1738.9, 1683.4, 1527.6 cm^{-1} ; ^1H NMR (DMSO- d_6 , 400 MHz): δ = 12.21 (s, 1H, NH), 8.33 (s, 1H, NH), 7.48 (m, 2H, Ar-H), 7.14 (m, 2H, Ar-H), 4.37 (d, $J=5.9\text{Hz}$, 2H, CH_2), 1.35 (s, 9H, $\text{C}(\text{CH}_3)_3$); ^{13}C NMR (DMSO- d_6 , 100 MHz) δ 156.2, 153.2, 79.7, 78.7, 28.7. LC-MS: (ESI) m/z calculated for $\text{C}_{13}\text{H}_{17}\text{N}_3\text{O}_2$ [$\text{M}+\text{H}$] $^+$ 248.14, observed 248.20.

***tert*-butyl (S)-1-(methoxycarbonyl)-2-(1*H*-benzo[*d*]imidazol-2-yl)ethylcarbamate (15b)**




White solid, 0.40 g, 92%; R_f 0.41 (9:1/ CH_2Cl_2 :MeOH); IR: 3300.1, 2979.8, 2618.5, 1888.4, 1676.4, 1650.9 cm^{-1} ; ^1H NMR (DMSO- d_6 , 400 MHz): δ = 12.21 (s, 1H, NH), 8.33 (s, 1H, NH), 7.49 (m, 2H, Ar-H), 7.27 (d, $J=8.3\text{Hz}$, 1H, Ar-H), 7.13 (m, 2H, Ar-H), 5.20 (q, $J=6.4\text{Hz}$, 1H, CH), 3.11 (dd, $J=6.4, 6.4\text{Hz}$, 1H, CH_2), 3.06 (s, 3H, OCH_3), 2.91 (dd, $J=6.4, 6.4\text{Hz}$, 1H, CH_2), 1.39 (s, 9H, $\text{C}(\text{CH}_3)_3$); ^{13}C NMR (DMSO- d_6 , 100 MHz) δ 169.8, 155.9, 155.4, 125.3, 122.1, 79.7, 78.7, 60.2, 46.7, 37.4, 37.1, 35.3, 28.7, 21.2. LC-MS: (ESI) m/z calculated for $\text{C}_{16}\text{H}_{22}\text{N}_3\text{O}_4$ [$\text{M}+\text{H}$] $^+$ 320.16, observed 320.20.

2-nonyl-1*H*-benzo[*d*]imidazole (15c)




White solid, 0.24 g, 90%; R_f 0.47 (9:1/CH₂Cl₂:MeOH); IR: 2937.4, 2894.1, 2857.2, 2562.8, 1949.0, 1926.9, 1886.9, 1739.9cm⁻¹; ¹H NMR (DMSO-d₆, 400 MHz): δ = 12.17 (s, 1H, NH), 7.45 (m, 2H, Ar-H), 7.10 (m, 2H, Ar-H), 2.79 (t, 2H, CH₂), 1.75 (t, 2H, CH₂), 1.24 (s, 12H, CH₂), 0.85 (t, 3H, CH₃); ¹³C NMR (DMSO-d₆, 100 MHz) δ 155.6, 121.4, 31.8, 29.4, 29.2, 29.1, 29.0, 28.0, 22.6, 14.4. LC-MS: (ESI) m/z calculated for C₁₆H₂₅N₂ [M+H]⁺ 245.20, observed 245.20.

2-undecyl-1*H*-benzo[*d*]imidazole (15d)




White solid, 0.449 g, 92%; R_f 0.24 (9:1/CH₂Cl₂:MeOH); IR: 3296.9, 2952.9, 2921.1, 2848.8, 2775.9, 1935.9, 1738.8cm⁻¹; ¹H NMR (DMSO-d₆, 400 MHz): δ = 12.18 (s, 1H, NH), 7.45 (m, 2H, Ar-H), 7.09 (m, 2H, Ar-H), 2.79 (t, 2H, CH₂), 1.75 (t, 2H, CH₂), 1.22 (s, 16H, CH₂), 0.84 (t, 3H, CH₃); ¹³C NMR (DMSO-d₆, 100 MHz) δ 155.6, 122.1, 31.9, 29.7, 29.7, 29.7, 29.5, 29.4, 29.4, 29.4, 22.7, 14.1. LC-MS: (ESI) m/z calculated for C₁₈H₂₉N₂ [M+H]⁺ 273.23, observed 273.20.

2-tridecyl-1*H*-benzo[*d*]imidazole (15e)




White solid, 0.46 g, 90%; R_f 0.26 (9:1/CH₂Cl₂:MeOH); IR: 3048.6, 2952.9, 2919.5, 2849.0, 1897.4, 1778.9cm⁻¹; ¹H NMR (DMSO-d₆, 400 MHz): δ = 12.15 (s, 1H, NH), 7.45 (m, 2H, Ar-H), 7.10 (m, 2H, Ar-H), 2.78 (t, 2H, CH₂), 1.75 (t, 2H, CH₂), 1.26 (s, 21H, CH₂), 0.85 (t, 3H, CH₃); ¹³C NMR (DMSO-d₆, 100 MHz) δ 155.6, 122.1, 31.9, 29.7, 29.7, 29.7, 29.5, 29.4, 29.4, 29.4, 22.7, 14.1. LC-MS: (ESI) m/z calculated for C₂₀H₃₃N₂ [M+H]⁺ 301.26, observed 301.30.

2-phenethyl-1*H*-benzo[*d*]imidazole (15f)



White solid, 1.1 g, %; R_f 0.24 (9:1/CH₂Cl₂:MeOH); IR: 3028.9, 2677.1, 1928.2, 1644.1, 1623.9, 1591.2cm⁻¹; ¹H NMR (DMSO-d₆, 400 MHz): δ = 12.26 (s, 1H, NH), 7.48 (m, 2H, Ar-H), 7.28 (m, 2H, Ar-H), 7.20 (m, 2H, Ar-H), 7.11 (m, 2H, Ar-H), 3.12 (s, 4H, (-CH₂)₂); ¹³C NMR (DMSO-d₆, 100 MHz) δ 154.8, 141.5, 128.8, 128.8, 126.5, 33.8, 30.9. LC-MS: (ESI) m/z calculated for C₁₅H₁₅N₂ [M+H]⁺ 223.12, observed 223.10.


Benzyl 1-((1*H*-benzo[*d*]imidazol-2-yl)methylcarbamoyl)-2-phenylethylcarbamate (15g)



15g

White solid, 0.22 g, 68%; R_f 0.38 (9:1/CH₂Cl₂:MeOH); IR: 3280.7, 1691.9, 1648.3, 1539.5, 1439.8 cm⁻¹; ¹H NMR (DMSO-d₆, 400 MHz): δ = 12.21 (s, 1H, NH), 8.77 (d, J =5.0 Hz, 1H, NH), 8.33 (s, 1H, NH), 7.52 (m, J =8.2, 3H, Ar-H), 7.22 (m, 14H, Ar-H), 4.93 (m, 2H, CH₂), 4.45 (s, 2H, CH₂), 4.33 (m, 1H, CH), 3.095 (dd, J =3.4, 3.8 Hz, 1H, CH₂), 2.84 (dd, J =3.4, 3.8 Hz, 1H, -CH₂); ¹³C NMR (DMSO-d₆, 100 MHz) δ 172.3, 156.4, 152.3, 138.6, 137.5, 129.7, 128.7, 128.5, 127.9, 126.7, 122.0, 79.7, 65.7, 49.1, 37.9, 37.7. LC-MS: (ESI) m/z calculated for C₂₅H₂₅N₄O₃ [M+H]⁺ 429.19, observed 429.20.


2-(5-methoxy-1*H*-indol-2-yl)-1*H*-benzo[*d*]imidazole (17a)



17a

White solid, 0.46 g, 92%; R_f 0.47 (9:1/CH₂Cl₂:MeOH); IR: 2991.5, 2829.5, 1705.8, 1674.6, 1623.9, 1602.3 cm⁻¹; ¹H NMR (DMSO-d₆, 400 MHz): δ = 12.93 (s, 1H, NH), 11.86 (s, 1H, NH), 7.67 (d, J =7.2 Hz, 1H, Ar-H), 7.56 (d, 1H, Ar-H), 7.34 (dd, J =8.8, 8.8 Hz, 1H, Ar-H), 7.23 (m, 2H, Ar-H), 6.83 (dd, J =8.8, 8.8 Hz, 1H, Ar-H), 3.79 (s, 3H, OCH₃); ¹³C NMR (DMSO-d₆, 100 MHz) δ 154.3, 146.7, 144.2, 135.2, 132.9, 129.4, 128.7, 122.9, 122.1, 118.9, 114.9, 114.1, 113.3, 113.2, 111.6, 102.2, 101.9, 55.7. LC-MS: (ESI) m/z calculated for C₁₆H₁₄N₃O [M+H]⁺ 264.11, observed 264.10.


5-fluoro-2-(5-methoxy-1*H*-indol-2-yl)-1*H*-benzo[*d*]imidazole (17b)



17b

White solid, 0.19 g, 53%; R_f 0.38 (1:1/hexanes:EtOAc); IR: 3437.4, 3036.9, 1866.5, 1620.4, 1605.2, 1576.2 cm⁻¹; ¹H NMR (DMSO-d₆, 400 MHz): δ = 13.06 (s, 1H, NH), 11.86 (s, 1H, NH), 7.59 (s, 1H, Ar-H), 7.41 (s, 1H, Ar-H), 7.35 (d, J =8.8 Hz, 1H, Ar-H), 7.15 (s, 1H, Ar-H), 7.06 (t, J =7.9 Hz, 2H, Ar-H), 6.84 (dd, J =2.4, 2.4 Hz, 1H, Ar-H), 3.78 (s, 3H, OCH₃); ¹³C NMR (DMSO-d₆, 100 MHz) δ 154.3, 132.9, 129.1, 128.6, 114.2, 113.2, 102.2, 102.1, 55.7. LC-MS: (ESI) m/z calculated for C₁₆H₁₃FN₃O [M+H]⁺ 282.10, observed 282.10.


5-chloro-2-(5-methoxy-1*H*-indol-2-yl)-1*H*-benzo[*d*]imidazole (17c)



17c

White solid, 0.21 g, 59%; R_f 0.47 (1:1/hexanes:EtOAc); IR: 3445.4, 2993.3, 2836.7, 1870.7, 1618.2, 1576.3 cm^{-1} ; $^1\text{H NMR}$ (DMSO- d_6 , 400 MHz): δ = 13.14 (s, 1H, NH), 11.91 (s, 1H, NH), 7.69 (s, 1H, Ar-H), 7.65 (dd, $J=8.6, 8.6\text{Hz}$, 1H, Ar-H), 7.55 (dd, $J=8.6, 8.6\text{Hz}$, 1H, Ar-H), 7.34 (d, $J=8.8\text{Hz}$, 1H, Ar-H), 7.23 (m, 2H, Ar-H), 6.84 (dd, $J=2.4, 2.4\text{Hz}$, 1H, Ar-H), 3.78 (s, 3H, OCH₃); $^{13}\text{C NMR}$ (DMSO- d_6 , 100 MHz) δ 154.3, 133.0, 128.8, 128.6, 114.4, 113.2, 102.4, 102.2, 79.7, 55.7. LC-MS: (ESI) m/z calculated for C₁₆H₁₃ClN₃O [M+H]⁺ 298.07, observed 298.10.


5-bromo-2-(5-methoxy-1*H*-indol-2-yl)-1*H*-benzo[*d*]imidazole (17d)



17d

White solid, 0.25 g, 70%; R_f 0.42 (1:1/hexanes:EtOAc); IR: 3315.3, 2938.2, 2832.4, 1738.1, 1628.0, 1569.4 cm^{-1} ; $^1\text{H NMR}$ (DMSO- d_6 , 400 MHz): δ = 13.14 (s, 1H, NH), 11.90 (s, 1H, NH), 7.8 (s, 1H, Ar-H), 7.71 (s, 1H, Ar-H), 7.60 (dd, $J=8.6, 8.4\text{Hz}$, 1H, Ar-H), 7.50 (dd, $J=8.6, 8.4\text{Hz}$, 1H, Ar-H), 7.35 (m, 2H, Ar-H), 7.15 (dd, $J=2.4, 1.7\text{Hz}$, 2H, Ar-H), 6.83 (dd, $J=2.4, 2.4\text{Hz}$, 1H, Ar-H), 3.79 (s, 3H, OCH₃); $^{13}\text{C NMR}$ (DMSO- d_6 , 100 MHz) δ 154.3, 148.0, 147.7, 145.7, 143.3, 136.5, 134.4, 133.0, 128.7, 125.6, 125.1, 121.1, 120.4, 115.1, 114.4, 113.2, 102.4, 102.2, 55.7. LC-MS: (ESI) m/z calculated for C₁₆H₁₃BrN₃O [M+H]⁺ 342.02, observed 342.10.


2-(5-methoxy-1*H*-indol-2-yl)-1*H*-benzo[*d*]imidazole-5-carbonitrile (17e)



17e

White solid, 0.25 g, 70%; R_f 0.40 (1:1/hexanes:EtOAc); IR: 3453.1, 3387.2, 3240.1, 2970.2, 2218.1, 1738.0, 1623.1, 1595.9 cm^{-1} ; $^1\text{H NMR}$ (DMSO- d_6 , 400 MHz): δ = 13.49 (s, 1H, NH), 11.97 (s, 1H, NH), 8.13 (s, 1H, Ar-H), 7.73 (d, $J=7.1\text{Hz}$, 1H, Ar-H), 7.61 (d, $J=8.2\text{Hz}$, 1H, Ar-H), 7.34 (d, $J=8.8\text{Hz}$, 1H, Ar-H), 7.23 (s, 1H, Ar-H), 7.15 (s, 1H, Ar-H), 6.85 (dd, $J=2.4, 2.4\text{Hz}$, 1H, Ar-H), 3.79 (s, 3H, OCH₃); $^{13}\text{C NMR}$ (DMSO- d_6 , 100 MHz) δ 154.3, 133.3, 128.6, 128.2, 120.5, 114.9, 113.4, 104.3, 103.4, 102.3, 55.7. LC-MS: (ESI) m/z calculated for C₁₇H₁₃N₄O [M+H]⁺ 289.11, observed 289.10.

2-(5-methoxy-1*H*-indol-2-yl)-5-methyl-1*H*-benzo[*d*]imidazole (17f)




17f

White solid, 0.32 g, 89%; R_f 0.42 (9:1/CH₂Cl₂:MeOH); IR: 3461.6, 3009.7, 2970.5, 1738.0, 1626.7, 1572.2 cm^{-1} ; $^1\text{H NMR}$ (DMSO- d_6 , 400 MHz): δ = 12.75 (s, 1H, NH), 11.79 (s, 1H, NH), 7.52 (dd, $J=8.2, 8.2\text{Hz}$, 1H, Ar-H), 7.45 (s, 1H, Ar-H), 7.41 (dd, $J=8.2, 8.2\text{Hz}$, 1H, Ar-H), 7.33 (s, 1H, Ar-H), 7.13 (d, $J=2.2\text{Hz}$, 1H, Ar-H), 7.07 (s, 1H, Ar-H), 7.02 (m, 1H, Ar-H), 6.81 (dd,


$J=2.4$, 2.4Hz, 1H, Ar-H), 3.78 (s, 3H, OCH₃), 2.45 (s, 3H, -CH₃); ¹³C NMR (DMSO-d₆, 100 MHz) δ 154.3, 146.6, 144.5, 133.2, 132.8, 131.0, 129.6, 124.4, 123.6, 118.6, 113.9, 111.3, 102.2, 101.6, 79.7, 55.7. LC-MS: (ESI) m/z calculated for C₁₇H₁₆N₃O [M+H]⁺ 278.13, observed 278.10.

Tert-butyl 1-(1H-benzo[d]imidazol-2-yl)-3-methylbutylcarbamate (19a)




White solid, 0.48 g, 96%; R_f 0.40 (1:1/hexanes:EtOAc); IR: 3345.2, 2958.5, 1680.1, 1524.6, 1443.6, 1365.3, 1316.2cm⁻¹; ¹H NMR (DMSO-d₆, 400 MHz): δ = 12.16 (s, 1H, NH), 7.50 (m, 2H, Ar-H), 7.30 (d, 1H, $J=8.1$ Hz, Ar-H), 7.14 (m, 2H, Ar-H), 4.84 (m, 1H, CH), 3.37 (s, 1H, NH), 1.74 (m, 2H, CH₂), 1.60 (m, 1H, CH), 1.34 (s, 9H, C(CH₃)₃), 0.92 (s, 6H, C(CH₃)₂); ¹³C NMR (DMSO-d₆, 100 MHz) δ 156.6, 155.8, 143.5, 134.5, 122.1, 121.4, 118.9, 111.7, 78.5, 48.1, 43.5, 28.7, 24.8, 23.2, 22.3. LC-MS: (ESI) m/z calculated for C₁₇H₂₆N₃O₂ [M+H]⁺ 304.20, observed 304.20.

Tert-butyl 1-(1H-benzo[d]imidazol-2-yl)-2-methylbutylcarbamate (19b)



White solid, 0.48 g, 96%; R_f 0.56 (1:1/hexanes:EtOAc); IR: 3323.4, 2965.7, 1681.3, 1526.9, 1443.3, 1364.9, 1331.9cm⁻¹; ¹H NMR (DMSO-d₆, 400 MHz): δ = 12.17 (s, 1H, NH), 7.51 (m, 2H, Ar-H), 7.21 (d, 1H, $J=8.8$ Hz, Ar-H), 7.15 (m, 2H, Ar-H), 4.64 (t, 1H, $J=8.2$ Hz, CH), 3.39 (s, 1H, NH), 1.74 (m, 2H, CH₂), 1.60 (m, 1H, CH), 1.34 (s, 9H, C(CH₃)₃), 0.86 (d, 3H, $J=2.2$ Hz, C(CH₃)), 0.74 (d, 3H, $J=6.7$ Hz, C(CH₃)); ¹³C NMR (DMSO-d₆, 100 MHz) δ 156.0, 155.8, 155.5, 121.9, 118.9, 111.8, 78.5, 54.4, 53.8, 38.8, 28.6, 26.2, 25.3, 16.0, 15.4, 11.8, 11.5. LC-MS: (ESI) m/z calculated for C₁₇H₂₆N₃O₂ [M+H]⁺ 304.20, observed 304.20.


Tert-butyl 1-(1H-benzo[d]imidazol-2-yl)-2-methylpropylcarbamate (19c)



White solid, 0.48 g, 94%; R_f 0.56 (1:1/hexanes:EtOAc); IR: 3325.7, 2964.0, 1681.4, 1529.7, 1443.3, 1365.3, 1302.5cm⁻¹; ¹H NMR (DMSO-d₆, 400 MHz): δ = 12.16 (s, 1H, NH), 7.51 (m, 2H, Ar-H), 7.19 (d, 1H, $J=8.8$ Hz, Ar-H), 7.14 (m, 2H, Ar-H), 4.57 (t, 1H, $J=7.8$ Hz, CH), 3.37 (s, 1H, NH), 2.21 (m, 1H, C(CH)), 1.38 (s, 9H, C(CH₃)₃), 0.92 (d, 3H, $J=5.4$ Hz, C(CH₃)), 0.79 (d,


3H, $J=5.2\text{Hz}$, C(CH₃); ¹³C NMR (DMSO-d₆, 100 MHz) δ 155.9, 155.5, 121.6, 118.9, 111.7, 78.5, 55.7, 32.6, 28.6, 19.7, 19.1. LC-MS: (ESI) m/z calculated for C₁₆H₂₄N₃O₂ [M+H]⁺ 290.19, observed 290.20.

Tert-butyl 2-(1H-benzo[d]imidazol-2-yl)pyrrolidine-1-carboxylate (19d)




White solid, 1.0 g, 98%; R_f 0.38 (1:1/hexanes:EtOAc); IR: 2976.3, 1696.1, 1660.9, 1428.3, 1383.9, 1360.1, 1322.9, 1307.7cm⁻¹; ¹H NMR (DMSO-d₆, 400 MHz): δ = 8.34 (s, 1H, NH), 7.49 (m, 2H, Ar-H), 7.13 (m, 2H, Ar-H), 4.95 (dd, 1H, $J=6.7, 3.6\text{Hz}$, CH), 3.61 (m, 1H, CH₂), 3.41 (m, 1H, CH₂), 2.29 (m, 2H, CH₂), 1.94 (m, 2H, CH₂), 1.39 (s, 9H, C(CH₃)₃); ¹³C NMR (DMSO-d₆, 100 MHz) δ 157.5, 156.9, 154.3, 153.8, 121.7, 115.2, 79.7, 79.2, 78.8, 56.2, 55.7, 47.2, 46.9, 38.7, 33.7, 32.4, 28.6, 28.2, 24.3, 23.6. LC-MS: (ESI) m/z calculated for C₁₆H₂₂N₃O₂ [M+H]⁺ 288.17, observed 288.20.

Tert-butyl 1-(1H-benzo[d]imidazol-2-yl)-2-(4-(benzyloxy)phenyl) ethylcarbamate (19e)




White solid, 0.42 g, 84%; R_f 0.40 (1:1/hexanes:EtOAc); IR: 3325.7, 2982.9, 1676.9, 1511.5, 1447.4, 1367.3, 1309.9, 1277.7, 1240.9, 1170.7, 1071.1, 1017.7, 962.1, 863.3, 813.8, 738.6cm⁻¹; ¹H NMR (DMSO-d₆, 400 MHz): δ = 12.22 (s, 1H, NH), 7.41 (m, 8H, Ar-H), 7.16 (m, 4H, Ar-H), 6.90 (d, 2H, $J=7.7\text{Hz}$, Ar-H), 5.04 (s, 2H, CH₂), 4.95 (q, 1H, $J=6.4\text{Hz}$, CH₂), 3.40 (s, 1H, NH), 3.29 (m, 1H, CH₂), 3.02 (t, 1H, $J=12.9\text{Hz}$, CH), 1.32 (s, 9H, C(CH₃)₃); ¹³C NMR (DMSO-d₆, 100 MHz) δ 157.4, 155.8, 155.6, 137.7, 130.7, 128.9, 128.2, 128.1, 114.9, 78.5, 69.6, 51.5, 28.6. LC-MS: (ESI) m/z calculated for C₂₇H₃₀N₃O₃ [M+H]⁺ 444.23, observed 444.20.

Tert-butyl 1-(1H-benzo[d]imidazol-2-yl)-2-(benzyloxy) ethylcarbamate (19f)




White solid, 0.42 g, 84%; R_f 0.34 (1:1/hexanes:EtOAc); IR: 3295.8, 2869.7, 1687.7, 1532.4, 1454.2, 1366.6, 1309.5 cm^{-1} ; ^1H NMR (DMSO- d_6 , 400 MHz): δ = 12.29 (s, 1H, NH), 7.52 (m, 2H, Ar-H), 7.37 (d, 2H, $J=8.2\text{Hz}$, Ar-H), 7.29 (m, 4H, 7.4Hz, Ar-H), 7.16 (m, 2H, Ar-H), 5.08 (m, 1H, CH), 4.53 (s, 1H, NH), 3.86 (m, 2H, CH_2), 3.38 (s, 2H, CH_2), 1.41 (s, 9H, $\text{C}(\text{CH}_3)_3$); ^{13}C NMR (DMSO- d_6 , 100 MHz) δ 155.8, 153.8, 138.7, 128.6, 127.9, 78.8, 72.4, 71.4, 49.7, 28.7. LC-MS: (ESI) m/z calculated for $\text{C}_{21}\text{H}_{26}\text{N}_3\text{O}_3$ $[\text{M}+\text{H}]^+$ 368.20, observed 368.20.

Tert-butyl 1-(1H-benzo[d]imidazol-2-yl)-2-(benzylthio) ethylcarbamate (19g)




White solid, 1.0 g, 98 %; R_f 0.45 (1:1/hexanes:EtOAc); IR: 3316.1, 2980.9, 1672.6, 1515.4, 1441.1 cm^{-1} ; ^1H NMR (DMSO- d_6 , 400 MHz): δ = 12.32 (s, 1H, NH), 7.58 (d, 1H, $J=7.4\text{Hz}$, Ar-H), 7.48 (m, 2H, Ar-H), 7.44 (m, 4H, Ar-H), 7.22 (m, 1H, Ar-H), 7.18 (m, 2H, Ar-H), 5.01 (q, 1H, $J=6.6\text{Hz}$, CH), 3.75 (s, 2H, CH_2), 3.11 (dd, 1H, $J=6.2, 6.1\text{Hz}$, CH_2), 2.85 (dd, 1H, $J=8.3, 8.3\text{Hz}$, CH_2), 1.43 (s, 9H, $\text{C}(\text{CH}_3)_3$); ^{13}C NMR (DMSO- d_6 , 100 MHz) δ 155.8, 154.7, 143.4, 138.8, 134.6, 129.4, 128.8, 127.3, 122.5, 121.7, 119.1, 111.9, 78.9, 49.4, 35.7, 35.4, 28.7. LC-MS: (ESI) m/z calculated for $\text{C}_{21}\text{H}_{26}\text{N}_3\text{O}_2\text{S}$ $[\text{M}+\text{H}]^+$ 384.17, observed 384.20.

Tert-butyl 1-(1H-benzo[d]imidazol-2-yl)-3-(benzyloxy) butylcarbamate (19h)




White solid, 0.47 g, 94%; R_f 0.40 (1:1/hexanes:EtOAc); IR: 3324.3, 2977.1, 1678.7, 1528.7 cm^{-1} ; ^1H NMR (DMSO- d_6 , 400 MHz): δ = 12.25 (s, 1H, NH), 7.49 (m, 2H, Ar-H), 7.30 (d, 1H, $J=9.4\text{Hz}$, Ar-H), 7.18 (m, 6H, Ar-H), 7.03 (d, 1H, $J=8.9\text{Hz}$, Ar-H), 5.02 (m, 1H, CH), 4.94 (m, 1H, CH), 4.47 (m, 2H, CH_2), 4.01 (m, 1H, NH), 3.37 (m, 2H, CH_2), 1.34 (s, 9H, $\text{C}(\text{CH}_3)_3$), 1.13 (d, 3H, $J=5.6\text{Hz}$, CH_3); ^{13}C NMR (DMSO- d_6 , 100 MHz) δ 155.9, 154.1, 139.1, 138.9, 128.5, 127.9, 127.8, 127.7, 79.6, 78.9, 76.5, 76.4, 70.7, 70.5, 53.4, 28.6, 17.0, 16.6. LC-MS: (ESI) m/z calculated for $\text{C}_{22}\text{H}_{28}\text{N}_3\text{O}_3$ $[\text{M}+\text{H}]^+$ 382.21, observed 382.20.

$N^{A,E}$ -bis-tert-butylloxycarbonyl-lysine-benzimidazole (19i)



White solid, 1.00 g, 96%; R_f 0.29 (1:1/hexanes:EtOAc); IR: 3317.9, 1693.9, 1677.2, 1530.9, 1439.8, 1393.0, 1364.3 cm^{-1} ; ^1H NMR (DMSO- d_6 , 400 MHz): δ = 12.15 (s, 1H, NH), 7.50 (m, 2H, Ar-H), 7.28 (d, 1H, $J=7.3\text{Hz}$, Ar-H), 7.14 (m, 2H, Ar-H), 6.79 (s, 1H, NH), 4.73 (m, 1H, CH), 3.37 (s, 1H, NH), 2.90 (m, 2H, CH_2), 1.84 (m, 2H, CH_2), 1.38 (s, 9H, $\text{C}(\text{CH}_3)_3$); ^{13}C NMR (DMSO- d_6 , 100 MHz) δ 156.3, 156.0, 155.8, 121.8, 78.6, 77.8, 49.9, 34.1, 29.6, 28.7, 28.7, 23.3. LC-MS: (ESI) m/z calculated for $\text{C}_{22}\text{H}_{35}\text{N}_4\text{O}_4$ $[\text{M}+\text{H}]^+$ 419.27, observed 419.30.


Tert-butyl 2-(phenoxyacetyl)-1-(1H-benzo[d]imidazol-2-yl)ethylcarbamate (19j)



19j

White solid, 0.45 g, 90%; R_f 0.46 (1:1/hexanes:EtOAc); IR: 3320.1, 2980.3, 1737.4, 1679.4, 1524.8, 1440.8, 1391.5, 1367.3, 1337.2 cm^{-1} ; ^1H NMR (DMSO- d_6 , 400 MHz): δ = 12.30 (s, 1H, NH), 7.56 (d, 1H, $J=8.00\text{Hz}$, Ar-H), 7.47 (m, 2H, Ar-H), 7.31 (m, 5H, Ar-H), 7.16 (m, 2H, Ar-H), 5.21 (q, 1H, $J=7.4\text{Hz}$, CH), 5.10 (s, 2H, CH_2), 3.40 (s, 1H, NH), 3.22 (m, 1H, CH_2), 2.95 (m, 1H, CH_2), 1.41 (s, 9H, $\text{C}(\text{CH}_3)_3$); ^{13}C NMR (DMSO- d_6 , 100 MHz) δ 170.6, 155.5, 154.6, 136.6, 134.9, 128.8, 128.3, 128.1, 121.6, 119.1, 111.9, 79.7, 78.9, 65.9, 46.6, 38.6, 28.7. LC-MS: (ESI) m/z calculated for $\text{C}_{22}\text{H}_{26}\text{N}_3\text{O}_4$ $[\text{M}+\text{H}]^+$ 396.19, observed 396.20.


Tert-butyl 3-((benzyloxy)carbonyl)-1-(1H-benzo[d]imidazol-2-yl)propylcarbamate (19k)



19k

White solid, 0.40 g, 80%; R_f 0.33 (1:1/hexanes:EtOAc); IR: 3312.3, 2977.1, 1737.5, 1677.3, 1525.8, 1453.8, 1391.4, 1366.9 cm^{-1} ; ^1H NMR (DMSO- d_6 , 400 MHz): δ = 12.22 (s, 1H, NH), 7.57 (dd, 1H, $J=6.9, 6.9\text{Hz}$, Ar-H), 7.46 (dd, 1H, $J=6.9, 6.9\text{Hz}$, Ar-H), 7.39 (m, 5H, Ar-H), 7.15 (m, 2H, Ar-H), 5.08 (s, 2H, CH_2), 4.85 (m, 1H, CH), 3.38 (s, 1H, NH), 2.49 (d, 2H, $J=12.0\text{Hz}$, CH_2), 2.29 (m, 1H, CH_2), 2.09 (m, 1H, CH_2), 1.40 (s, 9H, $\text{C}(\text{CH}_3)_3$); ^{13}C NMR (DMSO- d_6 , 100 MHz) δ 172.7, 155.8, 155.5, 143.4, 136.6, 134.7, 128.9, 128.4, 128.4, 122.3, 121.5, 119.0, 111.8, 79.7, 78.7, 65.9, 49.0, 30.6, 29.3, 28.7. LC-MS: (ESI) m/z calculated for $\text{C}_{23}\text{H}_{28}\text{N}_3\text{O}_4$ $[\text{M}+\text{H}]^+$ 410.21, observed 410.20.


Tert-butyl 1-(1*H*-benzo[*d*]imidazol-2-yl)-2-carbamoylethylcarbamate (19l)



19l

White solid, 0.48 g, 96%; R_f 0.41 (1:1/hexanes:EtOAc); IR: 3296.2, 2983.9, 1728.0, 1676.4, 1526.9, 1446.2, 1394.7, 1371.1, 1303.5 cm^{-1} ; ^1H NMR (DMSO- d_6 , 400 MHz): δ = 12.43 (s, 1H, NH), 8.32 (d, 1H, $J=1.2\text{Hz}$, NH), 7.79 (d, 1H, $J=8.3\text{Hz}$, Ar-H), 7.60 (dd, 1H, $J=7.2, 7.4\text{Hz}$, Ar-H), 7.48 (dd, 1H, $J=7.2, 7.4\text{Hz}$, Ar-H), 7.19 (t, 1H, $J=7.6\text{Hz}$, Ar-H), 5.19 (m, 1H, CH), 3.39 (s, 2H, NH_2), 3.13 (m, 1H, CH_2), 1.44 (s, 9H, $\text{C}(\text{CH}_3)_3$); ^{13}C NMR (DMSO- d_6 , 100 MHz) δ 155.5, 152.9, 143.1, 134.9, 122.8, 121.8, 119.2, 118.8, 112.0, 79.6, 79.3, 46.5, 28.6, 22.5. LC-MS: (ESI) m/z calculated for $\text{C}_{15}\text{H}_{21}\text{N}_4\text{O}_3$ $[\text{M}+\text{H}]^+$ 305.16, observed 305.20.


1,2,3,4-Tetrahydro-1-oxo-pyrido[1,2*a*]benzimidazole (19m)



19m

White solid, 0.48 g, 96%; R_f 0.53 (1:1/hexanes:EtOAc); IR: 3376.1, 2973.6, 1738.1, 1682.0, 1610.6, 1548.1, 1514.3, 1445.9, 1356.8, 1330.4, 1303.4 cm^{-1} ; ^1H NMR (DMSO- d_6 , 400 MHz): δ = 8.14 (m, 1H, Ar-H), 7.71 (m, 1H, Ar-H), 7.56 (d, 1H, $J=8.5\text{Hz}$, Ar-H), 7.39 (m, 2H, Ar-H), 5.12 (m, 1H, CH), 3.04 (m, 1H, NH), 2.88 (m, 1H, CH), 2.17 (m, 2H, CH_2), 1.45 (s, 9H, $\text{C}(\text{CH}_3)_3$), 0.92 (s, 6H, $\text{C}(\text{CH}_3)_2$); ^{13}C NMR (DMSO- d_6 , 100 MHz) δ 169.6, 155.6, 155.5, 142.7, 131.6, 125.4, 125.3, 119.9, 115.2, 78.9, 45.9, 31.8, 28.7, 27.6. LC-MS: (ESI) m/z calculated for $\text{C}_{16}\text{H}_{19}\text{N}_3\text{O}_3$ $[\text{M}+\text{H}]^+$ 302.15, observed 302.18.


Tert-butyl 1-(1*H*-benzo[*d*]imidazol-2-yl)-2-phenylethylcarbamate (19n)



19n

White solid, 1.0 g, 99%; R_f 0.40 (1:1/hexanes:EtOAc); IR: 3307.6, 1681.9, 1531.8, 1457.6, 1433.8, 1367.1, 1335.5, 1311.8 cm^{-1} ; ^1H NMR (DMSO- d_6 , 400 MHz): δ = 12.22 (s, 1H, NH), 7.51 (m, 1H, Ar-H), 7.40 (d, 1H, $J=8.3\text{Hz}$, Ar-H), 7.20 (m, 7H, Ar-H), 4.99 (m, 1H, CH), 3.36 (s, 1H, NH), 3.07 (t, 1H, $J=11.6\text{Hz}$, CH_2), 1.21 (s, 9H, $\text{C}(\text{CH}_3)_3$); ^{13}C NMR (DMSO- d_6 , 100 MHz) δ 155.8, 155.6, 138.6, 138.9, 129.7, 128.5, 126.7, 78.5, 51.3, 28.6. LC-MS: (ESI) m/z calculated for $\text{C}_{20}\text{H}_{24}\text{N}_3\text{O}_2$ $[\text{M}+\text{H}]^+$ 338.19, observed 338.20.


Tert-butyl 2-(4-(benzyloxy)phenyl)-1-(5-chloro-1H-benzo[d]imidazol-2-yl)ethylcarbamate (20)



20

White solid, 0.45 g, 90%; R_f 0.47 (7:3/hexanes:EtOAc); IR: 3318.2, 2930.1, 1675.5, 1607.9, 1510.4, 1445.3, 1371.1 cm^{-1} ; ^1H NMR (DMSO- d_6 , 400 MHz): δ = 12.41 (s, 1H, NH), 8.15 (s, 1H, Ar-H), 7.82 (m, 1H, Ar-H), 7.71 (m, 1H, Ar-H), 7.48 (m, 9H, Ar-H), 7.11 (m, 4H, Ar-H), 5.05 (m, 1H, CH), 3.37 (s, 2H, CH_2), 3.27 (m, 1H, CH_2), 3.01 (m, 1H, CH_2), 1.31 (s, 9H, $\text{C}(\text{CH}_3)_3$); ^{13}C NMR (DMSO- d_6 , 100 MHz) δ 157.4, 137.7, 130.7, 128.9, 128.2, 128.1, 118.4, 114.9, 78.6, 69.6, 28.6. LC-MS: (ESI) m/z calculated for $\text{C}_{27}\text{H}_{29}\text{ClN}_3\text{O}_3$ $[\text{M}+\text{H}]^+$ 478.19, observed 478.20.


Tert-butyl 2-(4-(benzyloxy)phenyl)-1-(5-bromo-1H-benzo[d]imidazol-2-yl)ethylcarbamate (21)



21

White solid, 0.46 g, 92%; R_f 0.47 (7:3/hexanes:EtOAc); IR: 3314.6, 2914.3, 1675.6, 1613.5, 1512.9, 1443.4, 1371.9 cm^{-1} ; ^1H NMR (DMSO- d_6 , 400 MHz): δ = 12.44 (s, 1H, NH), 7.77 (s, 1H, Ar-H), 7.60 (d, $J=8.3\text{Hz}$, 1H, Ar-H), 7.48 (m, 7H, Ar-H), 7.15 (dd, $J=8.1, 8.2\text{Hz}$, 2H, Ar-H), 6.89 (dd, $J=8.1, 8.2\text{Hz}$, 2H, Ar-H), 5.05 (m, 1H, CH), 3.37 (s, 2H, CH_2), 3.27 (m, 1H, CH_2), 3.01 (m, 1H, CH_2), 1.31 (s, 9H, $\text{C}(\text{CH}_3)_3$); ^{13}C NMR (DMSO- d_6 , 100 MHz) δ 157.4, 155.7, 144.9, 137.7, 130.7, 133.7, 129.4, 128.9, 128.2, 128.1, 124.9, 121.4, 120.7, 114.9, 114.5, 78.6, 69.6, 51.5, 38.9, 28.6. LC-MS: (ESI) m/z calculated for $\text{C}_{27}\text{H}_{29}\text{BrN}_3\text{O}_3$ $[\text{M}+\text{H}]^+$ 522.14, observed 522.10.

Benzyl 1-(1H-benzo[d]imidazol-2-yl)-2-carbamoyl ethylcarbamate (22)




22

White solid, 0.41 g, 82%; R_f 0.40 (1:1/hexanes:EtOAc); IR: 3303.1, 1693.3, 1528.7, 1440.3, 1328.9 cm^{-1} ; ^1H NMR (DMSO- d_6 , 400 MHz): δ = 12.52 (s, 1H, NH), 8.31 (d, 1H, $J=9.2\text{Hz}$, NH), 7.61 (dd, 1H, $J=7.6, 7.6\text{Hz}$, Ar-H), 7.49 (dd, 1H, $J=7.6, 7.6\text{Hz}$, Ar-H), 7.33 (m, 5H, Ar-H), 7.23 (m, 1H, Ar-H), 7.18 (m, 2H, Ar-H), 5.27 (q, 1H, $J=7.4\text{Hz}$, CH), 5.13 (q, 2H, $J=12.7\text{Hz}$, CH_2), 3.38 (s, 4H, NH_2 , CH_2), 3.33 (d, 1H, $J=5.0\text{Hz}$, CH), 3.18 (m, 1H); ^{13}C NMR (DMSO- d_6 , 100

MHz) δ 156.3, 152.6, 143.0, 137.2, 135.0, 128.9, 128.4, 128.3, 122.9, 121.9, 119.2, 118.8, 112.0, 66.4, 47.0, 22.4. LC-MS: (ESI) m/z calculated for $C_{18}H_{19}N_4O_3$ $[M+H]^+$ 339.15, observed 339.12.


Benzyl 1-(1*H*-benzo[*d*]imidazol-2-yl)-2-phenylethylcarbamate (23)



23

White solid, 1.0 g, 98%; R_f 0.54 (1:1/hexanes:EtOAc); IR: 3303.2, 1685.8, 1524.9, 1454.9, 1429.8, 1335.8 cm^{-1} ; 1H NMR (DMSO- d_6 , 400 MHz): δ = 12.33 (s, 1H, NH), 7.99 (d, 1H, $J=8.2$ Hz, Ar-H), 7.53 (m, 2H, Ar-H), 7.25 (m, 13H, Ar-H), 5.00 (q, 2H, $J=12.7$ Hz, CH), 3.40 (s, 4H, CH_2), 3.11 (t, 1H, $J=12.0$ Hz, NH); ^{13}C NMR (DMSO- d_6 , 100 MHz) δ 156.3, 155.5, 138.6, 137.5, 129.7, 128.8, 128.6, 128.1, 127.9, 126.8, 65.7, 51.9. LC-MS: (ESI) m/z calculated for $C_{23}H_{22}N_3O_2$ $[M+H]^+$ 372.17, observed 372.20.

Benzyl 1-(1*H*-benzo[*d*]imidazol-2-yl)-3-methylbutylcarbamate (24)




24

White solid, 0.45 g, 90%; R_f 0.40 (1:1/hexanes:EtOAc); IR: 3255.3, 1693.1, 1530.7, 1326.9 cm^{-1} ; 1H NMR (DMSO- d_6 , 400 MHz): δ = 12.25 (s, 1H, NH), 7.83 (d, 1H, $J=8.2$ Hz, Ar-H), 7.41 (m, 6H, Ar-H), 7.15 (m, 2H, Ar-H), 5.06 (q, 2H, $J=12.6$ Hz, CH_2), 4.89 (q, 1H, $J=7.7$ Hz, NH), 3.37 (s, 2H, CH_2), 1.79 (m, 1H, CH), 1.63 (m, 1H, CH), 0.92 (s, 6H, $C(CH_3)_2$); ^{13}C NMR (DMSO- d_6 , 100 MHz) δ 156.5, 156.4, 137.5, 128.8, 128.3, 128.2, 66.0, 48.6, 43.1, 24.8, 23.2, 22.2. LC-MS: (ESI) m/z calculated for $C_{20}H_{24}N_3O_2$ $[M+H]^+$ 338.19, observed 338.20.


NMR SPECTRA

tert-butyl (1*H*-benzo[*d*]imidazol-2-yl)methylcarbamate (15a)

¹H NMR




¹³C NMR




tert-butyl (S)-1-(methoxycarbonyl)-2-(1H-benzo[d]imidazol-2-yl)ethylcarbamate (15b)

¹H NMR




¹³C NMR




2-nonyl-1*H*-benzo[*d*]imidazole (15c)

¹H NMR




¹³C NMR




2-undecyl-1*H*-benzo[*d*]imidazole (15d)

¹H NMR




¹³C NMR




2-tridecyl-1*H*-benzo[*d*]imidazole (15e)

¹H NMR




¹³C NMR




2-phenethyl-1H-benzo[d]imidazole (15f)

¹H NMR




¹³C NMR




Benzyl 1-((1*H*-benzo[*d*]imidazol-2-yl)methylcarbamoyl)-2-phenylethylcarbamate (15g)

¹H NMR




¹³C NMR




2-(5-methoxy-1*H*-indol-2-yl)-1*H*-benzo[*d*]imidazole (17a)

¹H NMR




¹³C NMR




5-fluoro-2-(5-methoxy-1H-indol-2-yl)-1H-benzo[d]imidazole (17b)

¹H NMR




¹³C NMR




5-chloro-2-(5-methoxy-1H-indol-2-yl)-1H-benzo[d]imidazole (17c)

¹H NMR




¹³C NMR




5-bromo-2-(5-methoxy-1H-indol-2-yl)-1H-benzo[d]imidazole (17d)

¹H NMR




¹³C NMR




2-(5-methoxy-1H-indol-2-yl)-1H-benzo[d]imidazole-5-carbonitrile (17e)

¹H NMR




¹³C NMR




2-(5-methoxy-1H-indol-2-yl)-5-methyl-1H-benzo[d]imidazole (17f)

¹H NMR




¹³C NMR




Tert-butyl 1-(1H-benzo[d]imidazol-2-yl)-3-methylbutylcarbamate (19a)

¹H NMR




¹³C NMR




Tert-butyl 1-(1H-benzo[d]imidazol-2-yl)-2-methylbutylcarbamate (19b)

¹H NMR




¹³C NMR




Tert-butyl 1-(1H-benzo[d]imidazol-2-yl)-2-methylpropylcarbamate (19c)

¹H NMR




¹³C NMR




Tert-butyl 2-(1H-benzo[d]imidazol-2-yl)pyrrolidine-1-carboxylate (19d)

¹H NMR




¹³C NMR




Tert-butyl 1-(1H-benzo[d]imidazol-2-yl)-2-(4-(benzyloxy)phenyl)ethylcarbamate (19e)

¹H NMR




¹³C NMR




Tert-butyl 1-(1H-benzo[d]imidazol-2-yl)-2-(benzyloxy)ethylcarbamate (19f)

¹H NMR




¹³C NMR




Tert-butyl 1-(1*H*-benzo[*d*]imidazol-2-yl)-2-(benzylthio)ethylcarbamate (19g)

¹H NMR




¹³C NMR




Tert-butyl 1-(1H-benzo[d]imidazol-2-yl)-3-(benzyloxy)butylcarbamate (19h)

¹H NMR




¹³C-NMR




N^{a,e}-bis-butylloxycarbonyl-lysine-benzimidazole (19i)

¹H NMR




¹³C NMR




Tert-butyl 2-(phenoxy carbonyl)-1-(1H-benzo[d]imidazol-2-yl)ethylcarbamate (19j)

¹H NMR




¹³C NMR




Tert-butyl 3-((benzyloxy)carbonyl)-1-(1H-benzo[d]imidazol-2-yl)propylcarbamate (19k)

¹H NMR




¹³C NMR




Tert-butyl 1-(1H-benzo[d]imidazol-2-yl)-2-carbamoylethylcarbamate (19l)

¹H NMR




¹³C NMR




1,2,3,4-Tetrahydro-1-oxo-pyrido[1,2a]benzimidazole (19m)

¹H NMR




¹³C NMR




Tert-butyl 1-(1H-benzo[d]imidazol-2-yl)-2-phenylethylcarbamate (19n)

¹H NMR




¹³C NMR




Tert-butyl 2-(4-(benzyloxy)phenyl)-1-(5-chloro-1H-benzo[d]imidazol-2-yl)ethylcarbamate (20)

¹H NMR




¹³C NMR




Tert-butyl 2-(4-(benzyloxy)phenyl)-1-(5-bromo-1H-benzo[d]imidazol-2-yl)ethylcarbamate (21)

¹H NMR




¹³C NMR




Benzyl 1-(1H-benzo[d]imidazol-2-yl)-2-carbamoylethylcarbamate (22)

¹H NMR




¹³C NMR




Benzyl 1-(1*H*-benzo[*d*]imidazol-2-yl)-2-phenylethylcarbamate (23)

¹H NMR




¹³C NMR



Benzyl 1-(1*H*-benzo[*d*]imidazol-2-yl)-3-methylbutylcarbamate (24)

¹H NMR



¹³C NMR

